公开(公告)号：US20210106572A1

公开(公告)日：2021-04-15

申请号：US16952123

申请日：2020-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61P25/14 ,  A61K9/00

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20240398778A1

公开(公告)日：2024-12-05

申请号：US18814529

申请日：2024-08-25

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61K9/00 ,  A61P25/14

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20230165849A2

公开(公告)日：2023-06-01

申请号：US16952123

申请日：2020-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61P25/14 ,  A61K9/00

CPC classification number: A61K31/451 ,  A61P25/14 ,  A61K9/0053 ,  A61K9/0019

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20200179355A1

公开(公告)日：2020-06-11

申请号：US16789564

申请日：2020-02-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN ,  Neta ZACH

IPC: A61K31/44 ,  A61K9/00 ,  A61K31/426 ,  A61K31/4152 ,  A61K31/49 ,  A61K31/222 ,  A61K31/185 ,  A61K31/4748 ,  A61P25/14

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.